Cue Biopharma, Inc.

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a

Who: Cue Biopharma and Ono Pharmaceutical What: The two companies signed a deal to develop and commercialize CUE-401, Cue’s bispecific fusion protein in inflammatory and autoimmune diseases. Why:

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com